Immunterápia a vesedaganatok kezelésében

Translated title of the contribution: Immunotherapy of renal cell cancer

L. Géczi, Krisztián Nagyiványi, Anikó Maráz

Research output: Contribution to journalArticle


The authors briefly highlight the results of targeted therapy and present new solutions in kidney cancer immunotherapy. The important checkpoint inhibitors (anti-CTLA-4, -PD-1 and -PD-L1/2) and their combinations, together with the combinations of targeted drugs and immunotherapy are discussed. The newest checkpoint agents, vaccination and pegylated interleukin-2 are also presented. The most promising clinical trials (CheckMate-025, AGS-003, IMA 901) and the on-going first line phase III trials are shown in metastatic clear cell renal carcinoma.

Translated title of the contributionImmunotherapy of renal cell cancer
Original languageHungarian
Pages (from-to)126-131
Number of pages6
JournalMagyar onkologia
Issue number2
Publication statusPublished - Jun 6 2017

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Immunotherapy of renal cell cancer'. Together they form a unique fingerprint.

  • Cite this

    Géczi, L., Nagyiványi, K., & Maráz, A. (2017). Immunterápia a vesedaganatok kezelésében. Magyar onkologia, 61(2), 126-131.